Filing Flows › Twist Bioscience (TWST) › Q2 FY26 › vs Q2 FY25
Twist Bioscience (TWST) Q2 FY26 vs Q2 FY25 (year over year)
Twist Bioscience's revenue rose $17.9M (+19%) from $92.8M in Q2 FY25 to $111M in Q2 FY26. The biggest changes: DNA synthesis and protein solutions +$11.6M (+28%); NGS applications +$6.3M (+12%).
Twist Bioscience, Q2 FY26: revenue $111M (+19% year over year), operating margin -41.4%, net loss $44.0M, operating cash flow −$17.6M. The chart draws each line against Q2 FY25, the increases inside each band.
Every line
| Line | Q2 FY26 | Q2 FY25 | Change | % |
|---|---|---|---|---|
| NGS applications | $57.4M | $51.1M | $6.3M | +12% |
| DNA synthesis and protein solutions | $53.3M | $41.6M | $11.6M | +28% |
| Revenue | $111M | $92.8M | $17.9M | +19% |
| Other income, net | $1.9M | $2.4M | −$522K | -22% |
| Net loss | $44.0M | $39.3M | $4.7M | +12% |
| Costs & expenses | $157M | $135M | $22.1M | +16% |
| Operating costs | $157M | $134M | $22.2M | +17% |
| Income tax | $43K | $175K | −$132K | -75% |
| Cost of revenue | $53.6M | $46.8M | $6.8M | +15% |
| Research & development | $19.7M | $23.9M | −$4.2M | -18% |
| SG&A | $76.1M | $63.7M | $12.4M | +19% |
| Operating cash sources | $44.0M | $39.3M | $4.7M | +12% |
| Depreciation & amortization | $6.4M | $6.4M | $10K | +0.2% |
| Share-based compensation | $18.9M | $20.3M | −$1.4M | -7% |
| Working capital & other | $1.1M | −$390K | $1.5M | — |
| Cash used in operations | $17.6M | $13.0M | $4.6M | +35% |
| Net loss absorbed | $44.0M | $39.3M | $4.7M | +12% |
Questions
How much did Twist Bioscience's revenue grow year over year in Q2 FY26?
Twist Bioscience's revenue rose $17.9M (+19%) from $92.8M in Q2 FY25 to $111M in Q2 FY26.
What drove Twist Bioscience's revenue change in Q2 FY26?
DNA synthesis and protein solutions +$11.6M (+28%); NGS applications +$6.3M (+12%).